AVIRULENT SALMONELLA SP-10 VACCINE FOR SECRETORY IMMUNITY

这项研究计划的主要目标是开发一种口头 避孕疫苗，并研究这种口服疫苗的能力， 诱导不孕和女性生殖内分泌免疫 道。 即将开发的口服重组避孕疫苗将 由沙门氏菌的无毒菌株组成， 经工程改造以表达人类精子免疫原SP-10。 无毒力 沙门氏菌菌株会通过刺激肠道来诱导免疫力 相关淋巴组织[GALT]，以消除特定 抗体分泌细胞，将填充女性生殖 机关 将对食蟹猴Macca进行实验 束状肌 在工作的初始阶段，将对SP-10免疫原进行工程改造， 沙门氏菌无毒力菌株的稳定性和免疫原性 在小鼠中评估的构建体。 与此同时，方法 将被开发用于测量流体中的特定抗体浓度 猕猴卵泡、输卵管、子宫和子宫颈的粘液， 确定特异性抗体分泌细胞的数量和位置 在这些器官和循环中出现， 次免疫 已经开发出测量免疫反应的方法， 口服避孕疫苗对猴雌性生殖道的影响 卵巢、输卵管、子宫、子宫颈内的分泌免疫， 将在猴子中评价循环。 最重要的是，口服避孕药的抗生育潜力 将对疫苗进行评估。 不孕症将与 血清抗体以及分泌免疫的程度， 在女性的阴道内。 最后，血清中的SP-10抗体 和生殖道分泌物将被研究它们的能力， 抑制猴体外受精。 使用亲和纯化的抗体， 抑制作用所需的免疫球蛋白的精确化学计量 并将这些量与诱导的抗体水平进行比较 在卵泡、输卵管和宫颈分泌物中通过口服免疫接种。 将于年开发基于精子的重组口服避孕疫苗 该计划将提供有关输卵管分泌的基本信息 作为了解避孕模型广泛应用免疫力 疫苗行动。

The primary goal of this research proposal is to develop an oral contraceptive vaccine and to study the ability of this oral vaccine to induce infertility and secretory immunity within the female reproductive tract. The oral recombinant contraceptive vaccine to be developed will consist of avirulent strains of Salmonella which will be genetically engineered to express the human sperm immunogen SP-10. The avirulent strains of Salmonella will induce immunity by stimulating the gut associated lymphoid tissues [GALT] to dispel populations of specific antibody secreting cells which will populate the female reproductive organs. Experiments will be conducted on the cynomolgus monkey, Macca fascicularis. During the initial phase of the work the SP-10 immunogen will be engineered into avirulent strains of Salmonella and the stability and immunogenicity of the constructs evaluated in mice. In parallel with this goal, methods will be developed to measure specific antibody concentrations in the fluids and mucus of macaque ovarian follicles, oviducts, uterus and cervix and to determine the numbers and location of specific antibody secreting cells arising in these organs and in the circulation following parenteral immunization. Having developed methods of measuring immune responses in the monkey female tract, the effect of the oral contraceptive vaccine on secretory immunity within the ovaries, oviducts, uterus, cervix and circulation will be evaluated in monkeys. Most importantly, the anti-fertility potential of the oral contraceptive vaccine will be evaluated. Infertility will be correlated with levels of serum antibody as well as the degree to which secretory immunity was induced within the female tract. Finally, antibodies to SP-10 from serum and reproductive tract secretions will be studied for their ability to inhibit monkey in vitro fertilization. Using affinity purified antibodies, the precise stoichiometry of immunoglobulin required for inhibitory effects will be determined and these amounts compared to antibody levels induced within follicular, oviductal and cervical secretions by oral immunization. The sperm based recombinant oral contraceptive vaccine to be developed in this program will provide fundamental information on oviductal secretory immunity with wide application as a model for understanding contraceptive vaccine action.